Try our Advanced Search for more refined results

Amgen Inc. v. Sandoz Inc.

  1. May 13, 2015

    Sandoz Wants Amgen To Post $180M Bond For Losses

    Sandoz Inc. said Tuesday that Amgen Inc. should have to post a nearly $180 million bond to cover potential losses after the Federal Circuit temporarily blocked it from selling a copycat version of Amgen's blockbuster anti-infection drug Neupogen.

  2. May 06, 2015

    Amgen Wins Delay Of Sandoz Biosimilar At Fed. Circ.

    The Federal Circuit on Tuesday temporarily blocked Sandoz Inc. from selling a copycat version of Amgen Inc.'s blockbuster Neupogen, saying the product can't be sold until the court resolves a dispute over information-sharing requirements of the Affordable Care Act's biosimilars pathway.

  3. April 30, 2015

    Amgen Tells Fed. Circ. Sandoz Would 'Gut' Biosimilar Law

    Amgen Inc. fired back Tuesday at rival Sandoz Inc. in Amgen's appeal to the U.S. Federal Circuit over the Affordable Care Act's approval pathway for biosimilars, saying Sandoz's argument against Amgen's bid to block its biosimilar would "gut" a law guiding the approval process.

  4. April 27, 2015

    Sandoz Fights Amgen's Bid To Halt 1st Biosimilar Launch

    Sandoz Inc. urged the Federal Circuit to deny Amgen Inc.'s emergency bid to bar Sandoz's launch of the first-ever biosimilar drug under the Affordable Care Act, saying Friday the district court that denied the same request did not abuse its discretion or err in its factual findings.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!